Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.58 |
| ▸ | PDE6A | P16499 | 2/20 | 0.58 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.58 |
| ▸ | PDE2A | O00408 | 1/20 | 0.52 |
| ▸ | PDE8A | O60658 | 1/20 | 0.52 |
| ▸ | PDE9A | O76083 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.52 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30123159 | 0.83 | — | — | |
| SCHEMBL2483047 | 0.83 | — | — | |
| SCHEMBL2484196 | 0.83 | — | — | |
| SCHEMBL2482313 | 0.81 | — | — | |
| SCHEMBL2483757 | 0.81 | GRIA1 (0.58) | — | |
| SCHEMBL2482955 | 0.81 | — | — | |
| SCHEMBL1820734 | 0.79 | PDE10A (0.71) | PDE5APDE6APDE1BPDE3APDE2A | |
| SCHEMBL2484489 | 0.78 | — | — | |
| SCHEMBL2487528 | 0.78 | GRIA1 (0.64) | PDE5APDE6APDE1BPDE3A | |
| SCHEMBL3467020 | 0.76 | PDE5A (0.60) | PDE5APDE6APDE1BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2545055-B1 | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-09 | — | — | EP | disclosed |
| US-8859543-B2 | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-14 | — | — | US | disclosed |
| EP-2545055-A1 | IMIDAZO [1, 2 -A]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | Janssen Pharmaceutica, N.V. (BE) | 2013-01-16 | — | — | EP | disclosed |
| US-20120329792-A1 | IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | JANSSEN PHARMACEUTICA NV | 2012-12-27 | — | — | US | disclosed |
| WO-2011110545-A1 | IMIDAZO [1, 2 -A] PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329792-A1 | IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | PDE12, PDE10A, PDE5A | PDE5A 3/4885PDE6A 22/4885PDE1B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.